Actively Recruiting
Combined Immunosuppression for Pediatric Crohn's Disease
Led by Children's Hospital of Fudan University · Updated on 2026-03-19
128
Participants Needed
1
Research Sites
220 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.
CONDITIONS
Official Title
Combined Immunosuppression for Pediatric Crohn's Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 6 and 18 years
- Diagnosis of Crohn's Disease
- Pediatric Crohn's Disease Activity Index (PCDAI) greater than 30 or Simple Endoscopic Score for Crohn Disease (SES-CD) greater than 10 before treatment
- Receiving exclusive enteral nutrition or corticosteroids as first-line treatment with PCDAI greater than 10 or SES-CD greater than or equal to 3 after treatment
- Patient or legal guardian has signed informed consent
You will not qualify if you...
- History of biological agents targeting tumor necrosis factor (TNF)
- Previous Crohn's Disease-related surgery
- Presence of infections
- Presence of tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China, 201102
Actively Recruiting
Research Team
L
Lin Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here